Suppressive efficacies of antimicrobial agents against human peripheral-blood mononuclear cells stimulated with T cell mitogen and bacterial superantigen.
The immunomodulatory efficacies of 12 antimicrobial agents clinically used were examined against T cell mitogen- or bacterial superantigen-induced proliferation of peripheral-blood mononuclear cells of healthy subjects. Minocycline (CAS 13614-98-7), rifampicin (CAS 13292-46-1), trimethoprim (CAS 738-70-5), and ribavirin (CAS 36791-04-5) significantly inhibited the proliferation of mitogen-stimulated mononuclear cells at 1-100 microg/ ml (p < 0.001), whereas ofloxacin (CAS 82419-36-1) enhanced the proliferation (p < 0.001). Ampicillin (CAS 69- 53-4), lincomycin (CAS 859-18-7), vancomycin (CAS 1404-93-9), sulfamethoxazole (CAS 723-46-6), fosfomycin (CAS 26016-99-9), colistin (CAS 1264-72-8), and polymyxin B (CAS 1405-20-5) showed no significant effect. Minocycline, rifampicin, trimethoprim, and ribavirin also inhibited the proliferation of superantigen-stimulated peripheral-blood mononuclear cells at 1-100 microg/ml (<0.001), whereas ofloxacin stimulated the proliferation (p < 0.001). Rifampicin and minocycline at 10-100 microg/ml significantly inhibited interleukin-2 production from mitogen- or superantigen-stimulated peripheral-blood mononuclear cells (p < 0.025). These results suggest that certain kinds of antimicrobial agents inhibited the proliferation of mitogen- and superantigen-stimulated human peripheral-blood mononuclear cells and suppressed interleukin-2 production from these cells. The ofloxacin effect is immunostimulative, while the drug did not influence the interleukin-2 production.
Bohsei Pharmacy, Kanagawa, Japan.
Masaki
M
Maeda
Hidetoshi
H
Ishii
Sachiko
S
Tanaka
Kenji
K
Onda
Toshihiko
T
Hirano
D000328:Adult; D000890:Anti-Infective Agents / Q000494:pharmacology*; D000942:Antigens, Bacterial / Q000494:pharmacology*; D001427:Bacterial Toxins / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects; D003208:Concanavalin A; D016207:Cytokines / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D004768:Enterotoxins / Q000494:pharmacology*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000096:biosynthesis; D008297:Male; D008934:Mitogens / Q000494:pharmacology*; D009000:Monocytes / Q000187:drug effects*; D013268:Stimulation, Chemical; D018089:Superantigens / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects*
D000890:Anti-Infective Agents; D000942:Antigens, Bacterial; D001427:Bacterial Toxins; D016207:Cytokines; D004768:Enterotoxins; D007376:Interleukin-2; D008934:Mitogens; D018089:Superantigens; C030107:enterotoxin F, Staphylococcal; D003208:Concanavalin A